32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect
Metrics: PDF 964 views | HTML 1457 views | ?
Dinesh Chandra1, Benson Chellakkan Selvanesan1, Ziqiang Yuan2, Steven K Libutti2, Wade Koba3, Amanda Beck4, Kun Zhu1, Arturo Casadevall5, Ekaterina Dadachova6, Claudia Gravekamp1
1Albert Einstein College of Medicine, Department of Microbiology and Immunology, Bronx, NY 10461, USA
2Montefiore Medical Center, Medical Arts Pavilion, MMC-MAP, Bronx, NY 10467, USA
3Albert Einstein College of Medicine, Department of Radiology, MRRC, Bronx, NY 10461, USA
4Albert Einstein College of Medicine, Department of Pathology, Michael F. Price Center, Bronx, NY 10461, USA
5Johns Hopkins Bloomberg School of Public Health, Department of Molecular Microbiology and Immunology, Baltimore, MD 21205, USA
6Albert Einstein College of Medicine, Department of Radiology/Department of Microbiology and Immunology, Bronx, NY 10461, USA
Claudia Gravekamp, email: firstname.lastname@example.org
Keywords: listeria monocytogenes, 32P, pancreatic cancer, KPC, Panc-02, delivery platform
Received: August 24, 2016 Accepted: January 24, 2017 Published: February 06, 2017
Our laboratory has developed a novel delivery platform using an attenuated non-toxic and non-pathogenic bacterium Listeria monocytogenes that infects tumor cells and selectively survives and multiplies in metastases and primary tumors with help of myeloid-derived suppressor cells (MDSC) and immune suppression in the tumor microenvironment (TME). 32P was efficiently incorporated into the Listeria bacteria by starvation of the bacteria in saline, and then cultured in phosphorus-free medium complemented with 32P as a nutrient. Listeria-32P kills tumor cells through both 32P-induced ionizing radiation and Listeria-induced reactive oxygen species (ROS). The levels of 32P and Listeria were studied in various normal and tumor tissues, at sequential time points after injection of mice with pancreatic cancer (syngeneic model Panc-02). We found that 32P and Listeria predominantly accumulated in tumors and metastases, with their highest accumulation 4 hrs (32P) and 3 days (Listeria) after injection. Listeria also penetrated the transgenic KPC (conditionally express endogenous Kras-G12D and p53-R172H mutant alleles) pancreatic tumors and metastases. This is remarkable since KPC tumors, like human tumors, exhibit a stromal barrier, which prevents most drugs from penetrating the pancreatic tumors. Therapeutic treatment with Listeria -32P resulted in a strong reduction of the growth of pancreatic cancer at early and late stages in Panc-02 and KPC mice. These results highlight the power of Listeria as new delivery platform of anticancer agents to the TME. Not only were therapeutic levels of radioactive Listeria reached in tumors and metastases but the selective delivery also led to minimal side effects.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.